Categories
Pfizer virus

Pfizer CEO: Virus is here for years, but this could be the last wave with restrictions

Pfizer CEO Albert Bourla speaks during a ceremony in Thessaloniki, Greece, on October 12, 2021. (AP Photo/Giannis Papanikos, File)Pfizer CEO Albert Bourla said on Monday that while the “most likely scenario” is that the coronavirus will circulate for many years, he believes the current wave of infections will be the last to require restrictions. Bourla…

Categories
Exclusive Pfizer

EXCLUSIVE Pfizer to cut U.S. sales staff as meetings move to virtual

Pfizer logo seen outside their building in Manhattan, New York City, New York, U.S., March 2, 2021. REUTERS/Carlo Allegri/File PhotoRegister now for FREE unlimited access to Reuters.comJan 11 (Reuters) – Pfizer Inc (PFE.N) said on Tuesday it is reducing its U.S. sales staff as it expects doctors and other healthcare providers to want fewer face-to-face…

Categories
Pfizer seeks

Pfizer requests conditional EU authorization to COVID-19

Credit: Pixabay/CC0 Public Domain The European drug regulator said Monday it has started evaluating an application by Pfizer for its pill to treat the effects of COVID-19. The announcement comes as countries in much of the 27-nation bloc are reporting soaring numbers of infections as the highly transmissible omicron variant sweeps across the continent. The…

Categories
allow Pfizer

FDA could allow Pfizer boosters to 12-year-olds as soon as Monday

Younger adolescents may soon be eligible for COVID-19 booster vaccines, possibly by early next week. The U.S. Food and Drug Administration is planning on Monday to broaden booster eligibility to include 12- to 15-year-olds, sources told The New York Times. This would be for the Pfizer-BioNTech shot, currently the only COVID-19 vaccine approved for this…

Categories
authorizes Pfizer

FDA Authorizes Pfizer Antiviral Pill for COVID-19

Dec. 22, 2021 — The FDA on Wednesday granted emergency use authorization for a new antiviral pill to treat people with symptomatic COVID-19.Pfizer’s ritonavir plus nirmatrelvir, name brand Paxlovid, can now be taken by patients ages 12 and up who weigh at least 88 pounds The antiviral is only for people who test positive for the coronavirus, and…

Categories
final Pfizer

Pfizer: Final Data Shows COVID Pill Stays Strong Against Severe Illness

By Robin Foster HealthDay Reporter TUESDAY, Dec. 14, 2021 (HealthDay News) — Pfizer Inc. announced Tuesday that a final analysis shows its experimental antiviral pill Paxlovid sharply reduced hospitalizations and deaths among people at high risk for severe illness.The latest results, which reinforce an earlier analysis released in November, Pfizer’s drug cut hospitalizations and deaths…

Categories
COVID- Pfizer

Pfizer COVID Vaccine for Younger Children Hits Snag

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Dec. 17, 2021 — Pfizer’s COVID-19 vaccine for children ages 2 to 5 years old fizzled in clinical trials, the company said on Friday, signaling a further delay in getting a vaccine to preschoolers just as Omicron bears down on the U.S. In…

Categories
authorize Pfizer

FDA, CDC Authorize Pfizer Boosters for 16-year-olds

Dec. 9, 2021 — The FDA has authorized booster doses of Pfizer’s COVID-19 vaccine, clearing the way for millions of teenagers to get a third dose of vaccine starting 6 months after their second dose. The CDC quickly followed suit, allowing the boosters to begin immediately. The FDA said it was basing its emergency use authorization…

Categories
Moderna Pfizer

Pfizer or Moderna: Which COVID Vaccine Is Better?

By Robert Preidt HealthDay Reporter THURSDAY, Dec. 2, 2021 (HealthDay News) — Which coronavirus vaccine is best at beating COVID-19 — Moderna or Pfizer? New research hands that honor to Moderna: In what is billed as the first head-to-head comparison of the two shots, researchers analyzed the health records of nearly 440,000 U.S. veterans who…

Categories
Pfizer plans

Pfizer Plans to Seek Booster Approval for 16-Year-Olds

Nov. 30, 2021 — Pfizer and BioNTech plan to apply for FDA authorization this week for a booster COVID-19 vaccine for 16- and 17-year-olds.“We expect to share updates on this soon,” Kit Longley, a Pfizer spokesman, told The Washington Post.The FDA could authorize the extra dose within a week. If approved, the additional shot would…